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The inability of current recommendations to control the epidemic of diabetes, the speciﬁc failure of
the prevailing low-fat diets to improve obesity, cardiovascular risk, or general health and the
persistent reports of some serious side effects of commonly prescribed diabetic medications, in
combination with the continued success of low-carbohydrate diets in the treatment of diabetes
and metabolic syndrome without signiﬁcant side effects, point to the need for a reappraisal of
dietary guidelines. The beneﬁts of carbohydrate restriction in diabetes are immediate and well
documented. Concerns about the efﬁcacy and safety are long term and conjectural rather than data
driven. Dietary carbohydrate restriction reliably reduces high blood glucose, does not require
weight loss (although is still best for weight loss), and leads to the reduction or elimination of
medication. It has never shown side effects comparable with those seen in many drugs. Here we
present 12 points of evidence supporting the use of low-carbohydrate diets as the ﬁrst approach to
treating type 2 diabetes and as the most effective adjunct to pharmacology in type 1. They
represent the best-documented, least controversial results. The insistence on long-term random-
ized controlled trials as the only kind of data that will be accepted is without precedent in science.
The seriousness of diabetes requires that we evaluate all of the evidence that is available. The 12
points are sufﬁciently compelling that we feel that the burden of proof rests with those who are
opposed.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).“At the end of our clinic day, we go home thinking, “The
clinical improvements are so large and obvious, why don’t
other doctors understand?” Carbohydrate restriction is easily
grasped by patients: Because carbohydrates in the diet raise
the blood glucose, and as diabetes is deﬁned by high blood
glucose, it makes sense to lower the carbohydrate in the diet.
By reducing the carbohydrate in the diet, we have been able
to taper patients off as much as 150 units of insulin per day in
8 d, with marked improvement in glycemic controldeven
normalization of glycemic parameters.”
dEric Westman, MD, MHS [1].
Introduction
Reduction in dietary carbohydrate as a therapy for diabetes has
a checkered history. Before and, to a large extent, after the dis-
covery of insulin, it was the preferred therapeutic approach [2].
Only total reduction in energy intake was comparable as an
effective dietary intervention. The rationale was that both type 1
and type 2 diabetes represent disruptions in carbohydrate meta-
bolism. The most salient feature of both diseases is hyperglycemia
and the intuitive idea that reducing carbohydrate would amelio-
rate this symptom is borne out by experiment with no signiﬁcant
exceptions. Two factors probably contributed to changes in the
standard approach. The ascendancy of the low-fat paradigm
meant that the fat that would replace the carbohydrate that was
removed was now perceived as a greater threat, admittedly long
term, than the immediate beneﬁt from improvement in glycemia.
The discovery of insulin may have also cast diabetesdat least type
1das a hormone-deﬁciency disease where insulin (or more
recent drugs) were assumed to be a given and dietary consider-
ations were secondary. For these and other reasons, dietary car-
bohydrate holds an ambiguous position as a therapy.
Although low-carbohydrate diets are still controversial, they
have continued to demonstrate effectiveness with little risk and
good compliance. At the same time, the general failure of the
low-fat paradigm to meet expectations, coupled with continuing
reports of side effects of different drugs, indicates a need for
reevaluation of the role for reduction in carbohydrate. The cur-
rent issue seems to be whether we must wait for a long-term
randomized controlled trial (RCT) or whether we should eval-
uate all the relevant information. Practical considerations makeit virtually impossible to fund a large study of nontraditional
approaches. In any case, the idea that there is one kind of evi-
dence to evaluate every scientiﬁc question is unknown in any
science. Here we present 12 points of evidence supporting the
use of low-carbohydrate diets as the ﬁrst approach to treating
type 2 diabetes and as the most effective adjunct to pharma-
cology in type 1. They are proposed as the most well-established,
least controversial results. It is not known who decides what
constitutes evidence-based medicine but we feel that these
points are sufﬁciently strong that the burden of proof rests on
critics. The points are, in any case, intended to serve as the basis
for improved communication on this topic among researchers in
the ﬁeld, the medical community, and the organizations creating
dietary guidelines. The severity of the diabetes epidemic war-
rants careful and renewed consideration of our assumptions
about the diet for diabetes.
Deﬁnitions
A lack of agreed on deﬁnitions for low-carbohydrate diet has
been a persistent barrier to communication. We propose the
deﬁnitions in Table 1 to eliminate ambiguity. Each deﬁnition is
based on use in multiple publications by those authors who have
performed the experimental studies [3–6].
We recognize that levels of carbohydrate tolerance vary be-
tween individuals and even in one person over time. For example,
a very low-carbohydrate ketogenic diet (VLCKD) is deﬁned as
comprised of 20 to 50 g/d carbohydrate, but because of individual
variability, ketosis (blood ketone bodies >0.5 mM) may not occur.
12 Points of evidence
Point 1. Hyperglycemia is the most salient feature of diabetes.
Dietary carbohydrate restriction has the greatest effect on
decreasing blood glucose levels
Both type 1 and type 2 diabetes are defects in the res-
ponse to food, particularly to carbohydrates. The associated
hyperglycemia is both the most characteristic symptom and the
cause of downstream sequelae including insulin effects and
generation of advanced glycation end products (AGEs). The most
Table 1
Suggested deﬁnitions for different Forms of low-carbohydrate diets*
Very low-carbohydrate ketogenic diet (VLCKD)
 Carbohydrate, 20–50 g/d or <10% of the 2000 kcal/d diet, whether or not ketosis occurs. Derived from levels of carbohydrate required to induce ketosis
in most people.
 Recommended early phase (“induction”) of popular diets such as Atkins Diet or Protein Power.
Low-carbohydrate diet: <130 g/d or <26% total energy
 The ADA deﬁnition of 130 g/d as its recommended minimum.
Moderate-Carbohydrate Diet: 26%–45%
 Upper limit, approximate carbohydrate intake before the obesity epidemic (43%).
High-Carbohydrate Diet: >45%
 Recommended target on ADA websites.
 The 2010 Dietary Guidelines for Americans recommends 45%–65% carbohydrate. The average American diet is estimated to bew49% carbohydrate.
 Carbohydrate Consumption (NHANES)y:
 Men
 1971–1974: 42% (w250 g for 2450 kcal/d)
 1999–2000: 49% (w330 g for 2600 kcal/d)
 Women
 1971–1974: 45% (w150 g for 1550 kcal/d)
 1999–2000: 52% (w230 g for 1900 kcal/d)
ADA, American Diabetes Association; NHANES, National Health and Nutrition Examination Survey
* Derived from Accurso et al. [3] and references therein.
y NHANES is a series of studies conducted since 1960 that monitors >5000 people.
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taken as diagnostic. Glycemic control remains the primary target
of therapy in patients with type 1 and type 2 diabetes. It is
universally accepted that dietary carbohydrate is the main di-
etary determinant of blood glucose [7] and restriction shows the
greatest reduction in postprandial and overall glucose concen-
trations as well as HbA1c [3,6,8–14]. Whereas defects in repres-
sion of gluconeogenesis and glycogenolysis are the major causes
of hyperglycemia [8,15], carbohydrate is by far the greatest di-
etary contributor to blood sugar rises and, as expected, dietary
carbohydrate restriction reliably reduces glucose proﬁle.
Hussain et al. [14], for example, compared a VLCKD with a
low-calorie diet over a 24-wk period in 102 diabetic and 261
nondiabetic individuals. As shown in Figure 1, blood glucose
dropped more dramatically in the VLCKD group than in those
given the low-calorie diet. In the patients with type 2 diabetes,
however, after 24 wk, the average blood glucose level was
approximately 1 mM lower than in the low-calorie diet group.
More signiﬁcantly, the VLCKD group approached normal blood
sugar levels after 24 wk, whereas the low-calorie group’s blood
glucose concentration leveled out at 16 wk and remained
elevated. In the normal patients, blood glucose was already at
normal levels, and the VLCKD produced only a small effect.
The second panel in Figure 1 shows the effect of the two diets
on HbA1c levels. At 24 wk, patients with diabetes given theFig. 1. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
ketogenic diet.VLCKD achieved an HbA1c of 6.2%, whereas the average HbA1c in
the low-calorie diet group remained >7.5%.
Point 2. During the epidemics of obesity and type 2 diabetes,
caloric increases have been due almost entirely to increased
carbohydrates
Data from the National Health and Nutrition Examination Sur-
veys (NHANES) [16] indicate a large increase in carbohydrates as
the major contributor to caloric excess in the United States from
1974 to 2000 (Fig. 2). From the time of the ﬁrst NHANES study
(1974) to the last (2000), dietary carbohydrate in men rose from
42% to 49% of calories. For women, carbohydrate rose from 45% to
52%. The absolute amount of fat decreased for men during this
period and showed only a slight increase for women. The inset to
the Figure 2 reveals the rise, during this period, of the incidence of
type 2 diabetes to its current near epidemic proportions [17]. More
recently, one study [18] analyzed U.S. Department of Agriculture
availability data and found that the absolute fat availability had
increased slightly, but, as shown in the NHANES data [19], the in-
crease in carbohydrate was the predominant change.
These epidemiologic measurements are supported by
biochemical mechanisms. Continued stimulation of insulin pro-
duction can lead to an anabolic state that favors triglyceride (TG)
synthesis over lipolysis and generation of TG-rich lipoproteins [5].Redrawn from [14]. DM2, type 2 diabetes mellitus; VLCKD, very low-carbohydrate
Fig. 2. Macronutrient consumption during the epidemic of obesity and type 2 diabetes. Data from the National Health and Nutrition Examination Survey (NHANES) by year,
and from Centers for Disease Control and Prevention [19]. Inset: Incidence of diabetes (millions of people with diabetes by indicated year). Data from [17]. CHO, carbohydrate;
Prot, protein.
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the pancreas, create self-reinforcing cycles that are believed to
contribute to the onset of type 2 diabetes. Fatty liver leads to
impaired fasting glucosemetabolism and increased export of very-
low-density lipoprotein (LDL)-TG, which, in turn, increases fat
delivery to all tissues, including the insulin-producing pancreatic
islets. These liver and pancreas cycles lead to steadily decreasing b-
cell function [20]. The hepatic lipogenesis transcriptional program
is activated both directly and indirectly by carbohydrate ingestion.
Sterol regulatory element-binding protein and carbohydrate-
responsive element-binding protein are major transcriptional
regulators that are activated by carbohydrate signal to stimulate de
novo hepatic lipogenesis. Uncontrolled de novo lipogenesis causes
hepatic steatosis, which is closely associated with the onset of
obesity, insulin resistance, and type 2 diabetes [13].
Whatever the extent to which the correlation between
carbohydrate consumption and diabetes is causal, the lack of
association between the levels of dietary fat and diabetes in
humans is of real signiﬁcance. A lack of association is generally
considered strong evidence for a lack of causality.Point 3. Beneﬁts of dietary carbohydrate restriction do not require
weight loss
As described in point 1, low-carbohydrate diets generally
perform better than explicitly low-calorie diets but because
such trials are frequently hypocaloric by design or, by virtue of
the spontaneous reduction of intake, it is not always possible to
exclude the direct effect of calorie restriction or indirect hor-
monal effects due to feedback from changes in the adipocytes.
This is an important consideration in that it is well established
that the symptoms of type 2 diabetes improve with weight loss.
Insofar as the American Diabetes Association and other
agencies recommend low-carbohydrate diets, it is usually
solely for weight loss. Many people with type 2 diabetes,however, are not overweight and, conversely, many overweight
people never develop type 2 diabetes. People with type 1 are
not generally overweight although, at least anecdotally, the
weight gain associated with insulin therapy may be a reason
for poor compliance [21,22]. Additionally, several lines of
investigation support the idea that weight loss is not required
for improvement in glycemic control and other symptoms in
diabetes.
A series of well-designed experiments have been carried out
that demonstrated improvements in glycemic control and hor-
monal and lipid parameters under conditions where patients
were maintained at constant weight [9-11]. The most effective,
20%, was the lowest level of carbohydrate studied, although still
lowermight have beenmore effective. Results from a recent study
[9] are shown in Figure 3. Although the experimental protocol,
described by the authors as a low-bioavailable glucose (30% of
energy) diet, did not conform to the deﬁnitions in Table 1, they
indicate that improvement in glycemic control is possiblewithout
weight loss, evenwith only slightly lower carbohydrate. Studies in
which weight is lost and glycemic control is attained do not show
any correlation between the two outcomes (Fig. 4B). Given the
difﬁculties that most people have losing weight, this factor alone
provides an obvious advantage to low-carbohydrate diets.Point 4. Although weight loss is not required for beneﬁt, no
dietary intervention is better than carbohydrate restriction for
weight loss
The previous point emphasizes that low-carbohydrate diets
provide beneﬁt in the absence of weight loss. Nonetheless, such
diets consistently outperform low-fat diets for whatever time
period they are compared and frequently show dramatically better
results. Figure 4 shows two examples in people with diabetes.
One study [23] randomly allocated 26 people to either a low-
carbohydrate diet (40 g/d carbohydrate) or a “healthy-eating
Fig. 3. Twenty-four h glucose responses at baseline and after at 10 wk on a weight-maintaining low-bioavailable glucose diet (LoBAG30) for eight individuals. Time of
ingestion of breakfast (B), lunch (L), dinner (D), and snack (S) as indicated. Redrawn from reference [9].
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Thirteen people with type 2 diabetes and 13 controls without
diabetes were included. Weight loss was greater in the low-
carbohydrate arm (6.9 versus 2.1 kg). Most important, the study
reported individual responses, which are shown in Figure 4A.
Almost all participants in the low-carbohydrate arm were suc-
cessful at a loss of 2 kg as an arbitrary cutoff mark, whereas only
about half of the “healthy diet” group reached this mark.
Figure 4B compares weight loss on a VLCKD compared with a
low-fat diet. Three things are notable in this ﬁgure. First, weight
loss is better on the VLCKD than the low-fat diet: Inspection of
points along the x-axis shows that 70% of the low-fat individuals
lost <8 kg (right side of vertical dotted line), whereas 80% of the
VLCKD participants lost more than this amount, and along the y-
axis, more than one-third of the low-fat individuals increased
levels of glycated hemoglobin and only about 10% of the VLCKD
did. Finally, as pointed out previously, again by inspection, there
is little correlation between the two parameters.
Low-fat diets have in fact, shown very poor results, in the long
term, for weight loss in nondiabetic individuals. The Women’s
Health Initiative (WHI) is the most recent example. In the study[24], diet performance in 48,000 postmenopausal women was
compared with usual behavior. The low-fat intervention group
was encouraged to consume a 20% fat diet, rich in fruits, vege-
tables, and grains. Modest weight loss (average 2.2 kg) occurred
in the ﬁrst year. By the end of the intervention, this weight had
been regained. The authors made the very modest statement: “A
low-fat eating pattern does not result in weight gain in post-
menopausal women.” An editorial response to this study
published in JAMA, stated: “despite some successes, overall the
low-fat dietary approach has been a failure with the US public,
which is in desperate need of effective obesity treatment and
prevention strategies” [25]. The WHI was also distinguished by a
failure to show any beneﬁt in the prevention of diabetes or car-
diovascular disease [24,26,27].
It should also be emphasized that popular implementations
of low-carbohydrate diets like the Atkins diet [28,29] or Protein
Power [30] put no formal limit on caloric consumption on
the assumption that the greater satiety of protein and fat will
provide control of intake. As a result, it has been traditional to
carry out comparisons in which low-carbohydrate diets are ad
libitum, whereas the control diets, usually low-fat, are explicitly
Fig. 4. Effect of diet on weight loss in people with type 2 diabetes. (A) Data from Dyson et al. [23] comparing a low-carbohydrate diet with the “healthy-eating diet” of the
Diabetes UK agency. (B) Comparison of weight loss and changes in glycated hemoglobin. Very low-carbohydrate ketogenic diet (red triangles) is compared with a low-
glycemic index diet (blue squares). Data from [6].
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usually do better under these conditions supports the idea of
implicit control of total intake and has to be considered a clear
beneﬁt for this approach to weight loss.Point 5. Adherence to low-carbohydrate diets in people with type
2 diabetes is at least as good as adherence to any other dietary
interventions and is frequently signiﬁcantly better.
Adherence to low-carbohydrate diets, as formally measured
in clinical trials, is usually equal to or better than other diets
containing the same number of calories and is comparable with
that for many pharmacologic interventions. A comparison of theFig. 5. Comparison of percent completion of diet studies. Each point represents a
comparison from one of 19 studies. Low-carbohydrate values on the horizontal axis.
Low-fat values on vertical axis. Data from [33] which contains references to indi-
vidual studies.number of completers of carbohydrate-restricted vs fat-
restricted diets in 19 studies (Fig. 5) showed similar behaviors for
the two regimes. If anything, adherence was better on the low-
carbohydrate arms [33]. Comparable responses have been re-
ported elsewhere [34]. Positive results are usually attributed to
the effect of carbohydrate restriction on satiety and appetite
suppression due to behavioral effects or hormones. In a study of
The Active Low-Carber Forum, an online discussion group with
>150,000 members, a common assertion was that a low-
carbohydrate regimen provides the greatest degree of satisfac-
tion [35]. Protein and fat are known to induce satiety and to
reduce hunger-inducing blood sugar swings, likely via modula-
tion of insulin-mediated and signaling pathways that send
orexigenic signals to the brain. Additionally, patients who are on
insulin or insulin secretagogues are able to reduce their doses on
carbohydrate-restricted diets and ﬁnd they are less likely to need
to “feed” their insulin. As noted previously, in many studies, the
low-carbohydrate group is allowed unlimited access to food as
long as carbohydrate is reduced, whereas the low-fat control is
explicitly constrained to reduction in calories, an obvious beneﬁt
for compliance. In this sense, compliance is tied to the features of
the diet but encouragement by peers and health providers is a
major factor.Point 6. Replacement of carbohydrate with protein is generally
beneﬁcial
In practice, reduced-carbohydrate diets are not generally
high-protein diets except in comparison with low levels rec-
ommended in high-carbohydrate diets. It is also generally rec-
ommended that carbohydrate is replaced by fat. However, a large
number of RCTs have compared higher-protein, lower-carbohy-
drate diets (HPLCDs) with low-fat diets, and a number of sys-
tematic reviews and meta-analyses have assessed efﬁcacy and
short-term safety. These analyses have found that HPLCDs have
a more favorable effect onweight loss, body composition, resting
metabolic rate, and cardiovascular risk than fat-reduced diets.
One meta-analysis included 23 RCTs involving 1141 obese
nondiabetic participants who were reported in the literature
to be on a “low-carb” diet, regardless of the actual diet
Fig. 6. Hazard ratios and 95% conﬁdence intervals for coronary events and deaths in the different studies in a meta-analysis. Each line indicates a different cohort study with
either men (M) or women (W). Individual studies are indicated in the original meta-analysis [53]. Red is increased risk by substitution for SFAs. Green indicates lower risk if
SFA is substituted by indicated nutrient. Figure modiﬁed from [53]. Used with permission. CHO, carbohydrate; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
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group changes, as opposed to comparisons with low-fat or
other control diets, were measured. The lower carbohydrate di-
ets were associated with signiﬁcant decreases in body weight,
body mass index, TG levels, and blood pressure; additionally,
they showed improvement in several other metabolic and lipid
indicators.
A meta-regression of RCTs was used to determine the
comparative effects of protein and carbohydrate during energy
restriction [37]. The study examined 87 trials with 165 interven-
tion groups, comparing diets providing at least 1000 kcal/
d (4200 kJ/d). Diets that provided <35% to 41% of energy from
carbohydrate were associated with a 1.7 kg greater weight loss, a
0.7 kg greater loss of fat-free mass, and a 2 kg greater loss of fat
mass than diets with a higher percentage of energy from carbo-
hydrate. In studies lasting >12 wk, the effects were increased to
6.6 kg weight loss and 5.6 kg greater fat loss. Protein intakes
>1.05 g/kg were associated with 0.60 kg additional fat-free mass
retention compared with diets with protein intakes<1.05 g/kg. In
studies with duration >12 wk, this difference increased to 1.2 kg.
It has been concluded that HPLCDs favorably affect bodymass and
composition independent of energy intake which, in part, sup-
ports the proposed metabolic advantage of these diets [38,39].
Point 7. Dietary total and saturated fat do not correlate with risk
for cardiovascular disease
Several large and expensive clinical studies have been carried
out since the so-called diet–heart hypothesis was framed in
the middle of the 20th century [40,41]. From the originalFramingham study [42] to the WHI [26], as well as more than a
dozen additional studies, have failed to show an association
between dietary lipids and risk for cardiovascular disease (CVD).
There is now a large volume of literature of both scientiﬁc papers
[43–47] and popular books [48–51] documenting the failure of
attempts to support the diet–heart hypothesis. Few rebuttals
have been offered [52]. The very strong recommendations from
health agencies predicted that none of these trials should fail. In
fact, almost all of them have failed.
Three additional recent meta-analyses should help settle the
question of a causal link between dietary lipid and CVD [53–55].
Follow-up results were pooled from 11 major cohort studies that
followed the replacement of saturated fatty acids (SFAs) with
either polyunsaturated fatty acids (PUFA; Fig. 6A, B) or carbo-
hydrate [53].
The effect of replacing 5% of energy intake from SFA is shown
in Figure 6 [53]. Conclusions from the individual primary studies
are compelling. Almost all of the studies show no effect of
replacement of SFA with either carbohydrate or PUFA. The sta-
tistical rule is that if the 95% conﬁdence interval (CI) crosses 1,
there is no difference. The shaded areas in Figure 6, meant to
represent the differences between the pooled data, are very
small. More important, in our view, the statistical analysis is
inappropriate. Meta-analyses are appropriate for small under-
powered studies where there is a chance that combining them
may point to some unappreciated correlation. Figure 6, however,
collates large-scale, well-controlled studies that individually
showed no effect. It is questionable whether any statistical
method will allow one to average studies that have not shown a
statistical association and come upwith a meaningful correlation.
Fig. 7. Lack of association between dietary and plasma TG SFAs. In the green area,
an increase in dietary SFA is associated with a reduction in SFA in the TG fraction in
plasma. In the pink area, SFA inncreases even though dietary SFA is reduced. Data
from [61]. LFD, low-fat diet; SFA, saturated fatty acid; TG, triglyceride; VLCKD, very
low-carbohydrate ketogenic diet.
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hazard ratios increased when SFAs were replaced with carbohy-
drate and the study reported a “modest signiﬁcant direct associ-
ation between carbohydrates and coronary events.” A similar
analysis concluded that “replacing SFA with CHO [carbohydrate]
has no beneﬁts” [54], and others similarly concluded, “A meta-
analysis of prospective epidemiologic studies showed that there
is no signiﬁcant evidence for concluding that dietary saturated fat
is associated with an increased risk of CHD or CVD” [43,44]
In theend, the fact that so few individual studies foundanyeffect
is what is striking. None of the 15 studies on replacing saturated fat
with carbohydrate showed any effect on coronary events and only
two found a statistical effect on coronary deaths. Indeed, one of the
few studieswidely quoted as showing an effect of SFA is the Finnish
Mental Hospital Study whose scientiﬁc limitations have been
extensively analyzed [56], including the observation that manyFig. 8. Dependence of risk for myocardial infarction and microvascular end points on
smoking, presence of albuminuria, systolic blood pressure, high- and low-density lipopr
Hemoglobin (Hb).changes could be attributed to differences in antipsychotic medi-
cations. Looking at the studies in Jakobsen’s analysis (Fig. 6), and the
fact that some of these studies date from >20 y ago, it seems
reasonable to conclude that if there is any risk in replacing carbo-
hydratewithSFAs, it is still conjectural and longtermandshouldnot
override the established and immediate beneﬁt of the replacement.Point 8. Plasma saturated fatty acids are controlled by dietary
carbohydrate more than by dietary lipids
Despite the failure to establish real risk in point 8, a signiﬁcant
barrier to implementation of carbohydrate restriction as a therapy
in diabetes remains the traditional fear of the effect on blood lipids
and, for example, the tendency of dietary SFA to raise blood total
cholesterol [52,57]. The rationale for this concern followed from
the idea that because dietary SFA raised cholesterol and plasma
cholesterol was correlated with CVD [58], it was assumed that
dietary SFA would cause heart disease. The fallacy is that the data
were statistical and, to show cause, one had to show that the
peoplewhose cholesterol was raised by SFAwere the same people
whose cholesterol predicted CVD. In otherwords, it is necessary to
show a direct effect of dietary SFA on CVD. The previous point
emphasized that this has been impossible to do. Dietary SFA does
not correlate with CVD. On the other hand, it is increasingly un-
derstood that plasma SFAs are associated with increased risk for
CVD and insulin resistance [59]. in humans, plasma SFAs do not
correlate with dietary saturated fat but, rather, are more depen-
dent on dietary carbohydrates [5,60–62]. Elevated SFAs arise from
increased production of TG-containing lipoproteins, reduced
clearance, and the effect of dietary carbohydrate on de novo fatty
acid synthesis. In one study 40 patients diagnosed with metabolic
syndrome were treated with either a low-fat diet or a VLCKD. The
VLCKD group showed reduced plasma SFA levels compared with
the low-fat group, despite having consumed a threefold higher
intake of dietary saturated fat compared with the low-fat group.
Figure 7 shows that a low-carbohydrate diet was more likely to
reduce SFA in plasma TG fraction than a low-fat diet. It should be
mentioned, however, that an increase in dietary saturated fat is
not a necessary feature of a carbohydrate-restricted diet.
A further ambiguity in the literature arises from extrapolation
of rodent data. In some mouse models, dietary saturated fat is
correlated with plasma saturated fat but this result is not seen inhemoglobin A1c. Data adjusted for age at diagnosis of diabetes, sex, ethnic group,
otein cholesterol, and triglycerides. Modiﬁed from [65–67]. Used with permission.
Fig. 9. Comparison of low-glycemic index diet with high-cereal diet, and of low-
glycemic index diet with low-carbohydrate diet. Data from [6,70]. Redrawn from
[75]. CHO, carbohydrate; GI, glycemic index; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; TG, triglyceride; Total-C, total cholesterol.
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tently show negative effects of high-fat diets on obesity and in-
sulin resistance, in some cases, even in the absence of
carbohydrate [64]. These outcomes are not seen in humans and
one should be circumspect about generalizing results to a human
population. Among other species differences, some common
mouse lines are more resistant to nutritional ketosis.
Point 9. The best predictor of microvascular and, to a lesser extent,
macrovascular complications in patients with type 2 diabetes, is
glycemic control (HbA1c)
The results in point 7, that dietary SFA does not correlate with
CVD, did not speciﬁcally include individuals with diabetes. It is
known that patients with both type 1 and type 2 diabetes are at
increased risk for CVD. The United Kingdom Prospective Diabetes
Study (UKPDS), described next, addresses the question of the
relation between diabetes and CVD.
The UKPDS studied the incidence of macrovascular or mac-
rovascular complications in a population of 5102 patients with
newly diagnosed type 2 diabetes in 23 centers in the United
Kingdom between 1977 and 1991 [65–67]. The study found that
the key controlling variable was HbA1c. As HbA1c increased,
there was a corresponding increase in fatal and nonfatal
myocardial infarction (MI) events. There was a 14% decrease in
MI for every 1% reduction in HbA1c. The right panel in Figure 8
shows results for microvascular end points. There was a dra-
matic 37% decrease in these end points for microvascular risk for
each 1% reduction in HbA1c. It is important to consider that the
authors found that no speciﬁc thresholds of glycemia were
found. Risk appeared to increase for any HbA1c above normal,
taken in this study as 6%. Other studies had similarly failed to
identify any threshold effect of plasma glucose effects on car-
diovascular outcome [68]. The results are critical as a clear
demonstration that the increased risk for CVD in people with
diabetes is the diabetes itself as indicated by HbA1c. Point 1
emphasized that HbA1c is reliably reduced by low-carbohydrate
diets. The alternative, cited by the authors, of “adding insulin to
improve the relatively modest reduction in glycaemia achieved
with oral hypoglycaemic treatments can be constrained byreluctance from patients and providers because, in part, of side
effects such as weight gain.”
Point 10. Dietary carbohydrate restriction is the most effective
method (other than starvation) of reducing serum TGs and
increasing high-density lipoprotein
Carbohydrate restriction is the single most effective inter-
vention for reducing all of the features of metabolic syndrome
[5,62,69]. Figure 9 shows the results from a study comparing a
low glycemic index (low-GI diet) with a standard high-cereal
diet in 210 people with type 2 diabetes [70]. Results show a
1.7 mg/dL increase in high-density lipoprotein (HDL) levels for
the low-GI diet compared with a 0.2 mg/dL decrease for the
high-cereal diet. Coincidentally, at almost the same time,
another study [6] carried out a comparison, under very similar
conditions, of a low-GI diet with a VLCKD (<20 g/d carbohy-
drate). The difference in outcomes between these two groups
is striking. Figure 9 shows the results of a study in 84 obese
type 2 diabetics in comparison with the results from a
high-cereal/low-GI study that stands as the single most telling
indication of the potential for carbohydrate restriction in dia-
betes. The low-carbohydrate diet (reddish bar) shows the
greatest decrease in TG, as well as decrease in weight, HbA1c and
glucose and a greater increase in HDL.
Total and/or LDL cholesterol are the most commonly assessed
lipid markers for CVD risk despite the general recognition that
they are not good predictors. Several other parameters have been
shown to provide stronger evidence of risk and these tend to be
reliably improved by dietary carbohydrate restriction. These
include apolipoprotein (apo) B [71], ratio of total cholesterol to
HDL, higher populations of the smaller dense LDL known as
pattern B [72,73], as well as the ratio of apoB to apoA1. The ratio
of TG to HDL, which is also improved more by carbohydrate re-
striction is taken as a correlate of the smaller dense LDL, which is
not routinely measured [74].
Despite their routine measurement, a number of studies have
failed to support any connection between LDL cholesterol lowering
and improved mortality. During the ﬁrst 14 y of the Framingham
study, for every 1 mg/dL per year drop in cholesterol levels there
was a 14% increase in cardiovascular death and an 11% increase in
overall mortality [68]. Similar increase in mortality following a
drop in cholesterol was seen in other studies [76,77].
In our view, Figure 9 in combination with Figure 3 tells the
whole story on dietary interventions in type 2 diabetes. The
important point is that there is nothing in these studies that
suggests that there is any long-term harm as long as the protocol
is followed. One cannot start from the possibility of risk. In short-
term comparisons, it is the diet that does poorly that is of
concern in the long run. As in point 5, adherence is at least as
good on a low-carbohydrate regimen as any other dietary pro-
tocol or even some pharmacologic interventions. Common sense
dictates that the two most important factors in adherence are
efﬁcacydpeople will stay on a diet that worksdand encour-
agement from the health provider. The ﬁrst of these is a feature
of the diet. The second, again, is up to the health provider.
Point 11. Patients with type 2 diabetes on carbohydrate-restricted
diets reduce and frequently eliminate medication. People with
type 1 usually require lower insulin
Dietary carbohydrate restriction, because of its increased
effectiveness in glycemic control, frequently leads to reduction
and often complete elimination of medication in type 2 diabetes.
Table 2
Comparison of Effects of Diet on Medication Use at Baseline and at 3 mo Among
Participants Assigned to Either of the Indicated Diets*
Low-carbohydrate ketogenic diet (not calorie restricted)
1 Glimepiride, Actos, Exenatide, Metformin Dropped out of study
2 Metformin 500 mg bid No change
3 Metformin 850 mg bid No change
4 Metformin 1000 mg bid No change
5 Metformin 2000 mg No change
6 Metformin 500 mg Metformin discontinued
7 Glyburide 2.5 mg bid, Metformin
1000 mg bid
Glyburide and metformin
discontinued
8 Glipizide 2.5 mg, Metformin 1000 mg bid Glipizide discontinued
9 Glipizide 5 mg, Metformin 1000 mg bid Glipizide discontinued
10 Glyburide 2.5 mg bid, Metformin 500 mg Glyburide discontinued
11 Januvia 50 mg, Metformin 1000 mg bid Januvia discontinued
12 Glyburide 2.5 mg, Januvia 100 mg,
Metformin 1000 mg bid
Glyburide and januvia
discontinued
Moderate-carbohydrate calorie restricted
1 Metformin 500 mg No change
2 Metformin 500 mg No change
3 Metformin 500 mg bid No change
4 Metformin 500 mg bid No change
5 Metformin 500 mg bid No change
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on low-carbohydrate diets [78,79]. In both cases, carbohydrate
restriction reduces the number and severity of hyperglycemic
and hypoglycemic episodes. For people with type 1 diabetes,
decreasing the amount of carbohydrates in a meal reduces error
in determining insulin needs to match it.
Reduction of medication concomitant with reduction in
symptoms is considered a sign of efﬁcacy in most therapeutic
contexts. Table 2 shows results from a study that demonstrated
reductions in medication in patients on a VLCKD (20–50 g/d
carbohydrate) compared with a moderate carbohydrate diet that
was explicitly lower in calories [80]. In the study, of 11 patients
on medication in the VLCKD arm who ﬁnished the study, 5
reduced or discontinued one medication and 2 discontinued all
medications. Of the 13 patients on the moderate carbohydrate
diet, only 1 discontinued a sole medication. Similarly, another
study found that 17 of 21 patients with type 2 diabetes reduced
or discontinued diabetes medication upon carbohydrate re-
striction [81]. This result is a general feature of carbohydrate
restriction in type 2 diabetes [82–84].6 Metformin 1000 mg bid No change
7 Metformin 1000 mg bid No change
8 Glipizide 10 mg, metformin 1000 mg bid No change
9 Glimepiride 8 mg, januvia 1000 mg bid,
metformin 50 mg bid
No change
10 Glipizide 2.5 mg bid, metformin
1000 mg bid
No change
11 Glipizide 5 mg, Metformin 2000 mg,
Januvia 50 mg
No change
12 Metformin 850 mg tid Metformin lowered to
500 mg bid
13 Glipizide 5 mg, Metformin 500 mg bid,
Acarbose 50 mg tid
Glipizide discontinued
* Data from [80].
Table 3
Difference in Event Incidence (%) Hazard Ratio for Subsets of Patients in the
ACCORD Trial with Lower HbA1c Values or Who Had Not Had a Previous Event
(grey highlight)*
Event incidence (%) HR Statistically signiﬁcant
Previous cardiac event
Yes 10.9 1.1 No
No 5 0.8 Yes
Baseline HbA1c
8% 5.8 0.7 Yes
>8% 8.% 1.05 No
ACCORD, Action to Control Cardiovascular Disease in Diabetes; Hb, hemoglobin;
HR, hazard ratio
* Data from reference [85].Point 12. Intensive glucose lowering by dietary carbohydrate
restriction has no side effects comparable to the effects of
intensive pharmacologic treatment
The ACCORD (Action to Control Cardiovascular Disease in
Diabetes) trial was halted because of deaths from CVD [85]. After
3.5 y of follow-up, there were 257 deaths in the intensive-
therapy group compared with 203 in the standard-therapy
group (hazard ratio, 1.22; 95% CI, 1.01–1.46; P ¼ 0.04). Hypogly-
cemia requiring assistance and weight gain >10 kg were more
frequent in the intensive-therapy group (P < 0.001). The results
were interpreted as showing “a previously unrecognized harm of
intensive glucose lowering in high-risk patients with type 2
diabetes.” Results were reported as such in the popular media.
Logically, however, it is not the target but the method of trying to
attain it. Intensive use of medications in high-risk patients is a
more reasonable explanation. There are numerous concerns
about diabetes medications [85].
That the goal of lowering blood glucose has no inherent harm
to offset beneﬁt can be seen in the data for a subset of participants
in the ACCORD trial who had lower HbA1c values (Table 3). These
patients did not show the same risk as those with higher values.
Risks from several medications prescribed for diabetes have
been identiﬁed. Rosiglitazone is the subject of continuing debate.
It has been suggested that the agent posed a signiﬁcant risk for
MI and a risk for death from CVD, the latter of “borderline sig-
niﬁcance.” The original result has been disputed [86–89] and the
fate of the drug is unknown, but no such ambiguity attaches to
dietary carbohydrate restriction.
Discussion
The need for a reappraisal of dietary recommendations stems
from the following:
1. General failure to halt the epidemic of diabetes under cur-
rent guidelines.
2. The speciﬁc failure of low-fat diets to improve obesity, car-
diovascular risk, or general health (points 1 and 4).
3. Constant reports of side effects of commonly prescribed
diabetic medications, some quite serious (points 12).
4. Most importantly, the continued success of low-
carbohydrate diets to meet the challenges of improvementin the features of diabetes and metabolic syndrome in the
absence of side effects.
The beneﬁts of carbohydrate restriction are immediate and
well documented. Concerns about the efﬁcacy and safety of
carbohydrate restriction are long term and conjectural rather
than data driven. Most objections stem from the proposed dan-
gers of total or saturated fat embodied in the so-called diet–heart
hypothesis. At this point, the diet–heart hypothesis has had a
record of very limited clinical or experimental success to support
its position. The issue has become the subject of strong
reaction in both the scientiﬁc literature and the popular press
[48,50,51,90] (point 8).
It is well established that weight loss, by any method, is
beneﬁcial for individuals with diabetes. The advantages to a low-
carbohydrate approach are that, because of greater satiety,
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required. There may be de facto reduction in calories without the
need for replacement. The extent to which there is replacement,
either fat or protein may be beneﬁcial (points 4 and 6) although,
in practice, fat is recommended unless there is already lower
protein. Concerns about high protein in carbohydrate restriction
have been raised but, except for those people with existing
kidney disease, none has ever been demonstrated [91]. Protein
also tends to a stable self-limiting part of the diet. Perhaps most
important, if carbohydrate is low, glycemic control and other
physiologic parameters are improved even if weight loss is not
accomplished (point 3).
Finally, it should be recognized that the use of low-
carbohydrate diets is not a recent experiment and may well
approximate the diet used by much of humanity for tens of
thousands of years before the rise of agriculture. Current
knowledge dictates that carbohydrate restriction should be a
default treatment for type 2 diabetes and a default adjunct
therapy for type 1. Given the superior outcomes of carbohydrate-
restricted diets, patients should not be discouraged from
adhering to them as is frequently observed. They should, in fact,
be encouraged to follow this approach.
The 12 points of evidence represent the best investigated and
least conjectural ideas on diabetes. It is unlikely that one dietary
strategy, any more than one kind of pharmacologic treatment
will be best for all individuals. Patients can refuse medication or
opt out of surgery, but they cannot not be on a diet and low-
carbohydrate is the reasonable place to start. We recognize
that there are many complications and issues that are still not
understood, however, we have tried to isolate the factors that
have the fewest contradictions.
This review emphasized the most obvious principles. An
anonymous reviewer, however, raised two important if more
conjectural points. We were asked “To specify role of starch
versus mono- and disaccharides in carbohydrate-semi-restricted
diet (optimal proportions).” and “In discussion to draw more
attention to the possible disadvantages of low-carbohydrate diet
in people with diabetes.”
Role of starch versus mono- and disaccharides
Replacement of carbohydrate with fat or, in some cases, with
protein, is beneﬁcial in both types of diabetes leading to better
glycemic control, weight loss, cardiovascular risk markers, and
reduction in medication. This is what we know. That is what is
established in well-controlled experiments in individuals with
diabetes (points 1, 3, and 10). The evidence does not contain
strong data onwhich carbohydrates should be removed (or even
what the effect of different fats of protein might be). On ﬁrst
principle, glucose is of greatest importance in diabetes. The
sudden interest in fructose and sucrose as unique types of car-
bohydrate has made the discussion quite controversial. Both the
scientiﬁc [92,93] and popular literature [94] have been unre-
strained in attributing harm to fructose. Generally, fructose is
known to have unique effects compared with glucose, although
most of these are seen on a high-carbohydrate diet [95] and
there may be little difference as carbohydrate is lowered. It is
likely that on a low-carbohydrate diet, most fructose that is
consumed will be converted to glucose. We have provided a
perspective on the metabolism of fructose [96] where we
emphasize its integration into general carbohydrate metabolism.
The fact that up to 60% of ingested fructose can be converted to
glucose makes the analysis of which sugar does what very
difﬁcult.The deﬁnitive experiment, testing whether removing fructose
is preferable to removing glucose in the implementation of a
low-carbohydrate diet has never been performed. This is pre-
sumably due to the poor acceptance of low-carbohydrate diets in
general [4]. One study showed that glycemic response was lower
after ingestion of a low-starch meal with 43% total carbohydrate
and high levels of fruit compared with a high-starch, high-car-
bohydrate meal or a 40% carbohydrate “typical American meal”
[97]. There was also, as expected, a lower 24-h integrated serum
insulin response. The results demonstrate the value of specif-
ically removing starch, although it was not determined whether
removing sugar would be equally effective or better. As above,
this group has also shown good results simply by reducing
glucose (point 3).
Because of the limited insulin effect, it was once thought that
fructose might be an acceptable source of carbohydrate, but this
turned out to be questionable and may actually have a delete-
rious effects if administered intravenously alone. Analysis of the
hepatic metabolism shows that the liver expects the two sugars
to appear together [96], fructose (e.g., increases glucokinase
activity).
The reviewer’s original question is framed in terms of
“carbohydrate-semi-restricted diet (optimal proportions).” It is
unlikely that there is a general answer. As a guide for the patient
with diabetes, the prescription of many agencies to “eat to the
meter” seems like a good one.Possible disadvantages of low-carbohydrate diet in people with
diabetes
To assess the disadvantages of carbohydrate restriction for
individuals with diabetes, one has to ask what the standard is
and where it came from. The idea that there is an effective diet of
known macronutrient composition, one tested in long-term, or
even short-term trials, that is beneﬁcial in treating diabetes is
implied by the question. To our knowledge, no such diet exists.
The more dietary carbohydrate, the more medication will be
required (point 11). The disadvantage to a low-carbohydrate diet,
as in any intervention, will rest with individual choices. Low-
carbohydrate diets generally have better compliance (point 5)
but individuals vary in tastes and assessment of risk–beneﬁt
perceptions.
The ﬂipside of the beneﬁt from reduced medication (point
11) presents a real potential disadvantage. Because of the effec-
tiveness of carbohydrate restriction on glycemic control, there is
a danger of hypoglycemia for those patients on glucose-lowering
medication. It is recommended that medication be reduced in
advance of initiating a low-carbohydrate diet. Personal com-
munications suggest that there are a variety of strategies for
reducing insulin or other drugs. Whether the patient (or the
physician) knows this is potentially serious question. In-
structions for the study in reference [80], for example, provide
the following guide:
“Metformin was continued for the duration of the study un-
less the participant or his/her doctor requested it be lowered, at
which point the dose was cut in half or discontinued completely.
Sulfonylurea doses were reduced in half if the entry HbA1c was
<7.5% or discontinued if the participant was on aminimum dose.
Sulfonylurea was discontinued if predinner glucose levels went
below 110 mg/dL despite prior dose reduction; thiazolidine-
diones were continued for participants with starting with a
HbA1 c above 7% and discontinued for thosewith starting HbA1 c
below 7%.”
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What evidence would be required to change the current
recommendations for dietary treatment in diabetes? Evidence-
based medicine tends to emphasize RCTs as a gold standard.
Such absolute requirements, however, are unknown in any sci-
entiﬁc discipline. As in a court of law, science admits whatever
evidence is relevant [98]. Following the legal analogy, one has to
ask: Who decides on the admissibility of the evidence? The
parody by Smith and Pell [99] has been described as both funny
and profound in illustrating how there is not a single type of
experiment that ﬁts every scientiﬁc question. Given the current
state of research funding and the palpable bias against low-
carbohydrate approaches [4], it is unlikely that an RCT can be
performed that will satisfy everybody. The seriousness of dia-
betes suggests that we have enough evidence of different types
to reevaluate our current recommendations for treatment.
This review has described 12 points of evidence based on
published clinical and experimental studies and the experience
of the authors. The points are supported by established princi-
ples in biochemistry and physiology and emphasize that the
beneﬁts are immediate and documented while the concerns
about risk are conjectural and long term.
We would recommend that government or private health
agencies hold open hearings on these issues inwhich researchers
in carbohydrate restriction can make their case. We think that
traditional features of the analysis of evidence such as vigorous
cross-examination should be part of the process. We suggest that
open discussion with all sides contributing will be valuable. The
seriousness of diabetes suggests that a bench decree will be
inappropriate.References
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